Trial Profile
A 4-Stage, Open-label, Multicenter Study Including Long-term Extension to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Teduglutide (Primary)
- Indications Short bowel syndrome
- Focus Therapeutic Use
- Sponsors NPS Pharmaceuticals; Shire
- 19 May 2020 Results from short-term (24-week) and long-term (30-month) extension periods of the trial published in Gasteroenterology in conjunction with Digestive Disease Week 2020.
- 21 Dec 2018 Status changed from active, no longer recruiting to completed.
- 13 Aug 2018 Planned End Date changed from 2 Mar 2020 to 4 Nov 2018.